4D Molecular Therapeutics, Inc. is a leading late stage biotechnology company advancing durable and disease targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients. The company focuses on developing genetic medicines using customized and evolved adeno associated virus vectors created from its proprietary Therapeutic Vector Evolution platform. This platform applies directed evolution in non human primate models to select vectors that target disease tissues with high unmet need using routine and local routes of administration. By engineering vectors for specific indications the company aims to overcome limitations of conventional adeno associated virus approaches such as inflammation toxicity high dose requirements and neutralization by pre existing antibodies. The resulting product candidates are designed to deliver sustained transgene expression after a single administration thereby reducing treatment burden for patients with chronic conditions.

The company generates revenue primarily through collaboration agreements licensing deals and grant funding that support the advancement of its product candidates. Notable arrangements include an upfront payment of eighty five million dollars from Otsuka Pharmaceutical for rights to develop and commercialize 4D 150 in Asia Pacific markets and potential milestone payments and tiered royalties based on future sales. Additionally the company has received multiple grants from the Cystic Fibrosis Foundation totaling several million dollars to fund research and development of its pulmonology programs. These sources provide non dilutive capital to progress clinical trials manufacturing activities and preparatory work for potential commercial launch. The business model relies on advancing candidates through clinical proof of concept and then securing partnership or licensing deals that unlock further value.

The company operates through the following segments: Retina and Pulmonology.

• The Retina segment focuses on creating genetic medicines for eye diseases using the proprietary R100 vector designed for efficient intravitreal delivery to retinal tissues. Its lead product candidate 4D 150 combines the R100 vector with a dual transgene expressing aflibercept and VEGF C RNAi to address vascular endothelial growth factor mediated conditions such as wet age related macular degeneration and diabetic macular edema. The segment also includes 4D 175 which targets geographic atrophy and is currently awaiting further financing to advance development. Manufacturing efforts for the retina programs leverage the company’s internal cGMP capabilities and partnerships with contract development and manufacturing organizations to produce clinical trial material at scale. The segment benefits from regulatory recognitions including RMAT and PRIME designations for 4D 150 which highlight its potential to meet significant unmet medical needs.

• The Pulmonology segment develops genetic medicines for lung diseases using the proprietary A101 vector engineered for aerosol delivery and resistance to pre existing antibodies. Its lead product candidate 4D 710 delivers a codon optimized CFTR transgene to restore cystic fibrosis transmembrane regulator function in lung epithelial cells and is currently in phase two clinical trials supported by funding from the Cystic Fibrosis Foundation. Another candidate 4D 725 targets alpha 1 antitrypsin deficiency and remains in preclinical development with backing from the California Institute for Regenerative Medicine. The segment emphasizes a modular approach where the same vector can be paired with different transgenes to address multiple lung indications thereby increasing development efficiency and reducing risk. Manufacturing for pulmonology candidates utilizes aerosol compatible processes and the company’s in house facilities to produce material for toxicology studies and early phase trials.

The company holds a distinctive position in the genetic medicine field due to its proprietary Therapeutic Vector Evolution platform which creates vectors optimized for specific tissues and capable of evading human antibody responses. In the retina arena it faces competition from established programs such as AbbVie’s anti VEGF gene therapy program REGENXBIO’s gene therapy programs and Adverum’s gene therapy candidate as well as emerging approaches from EyePoint Ocular Therapeutix Kodiak Sciences and Merck. Its advantages include the ability to achieve broad retinal coverage via a routine intravitreal injection the potential to inhibit multiple VEGF factors and a favorable safety profile demonstrated in long term follow up data. In pulmonology the company competes with Vertex Pharmaceuticals’ CFTR modulators and early stage entrants such as Sionna Therapeutics Krystal Biotech Arcturus and Recode Therapeutics while differentiating itself through a vector designed for aerosol delivery mucous barrier penetration and durability of expression that may allow less frequent dosing compared to daily small molecule therapies. The platform’s ability to generate unique capsid sequences from a library of approximately one billion variants provides a scalable source of novel intellectual property that can be applied across diverse disease areas. This capability together with proven preclinical success in non human primates gives the company a defensible edge as it advances its pipeline toward commercialization.

The company’s primary customers are patients suffering from retinal and lung diseases who receive treatment through ophthalmology and pulmonology providers. In addition the company collaborates with specific partners such as Otsuka Pharmaceutical which holds rights to develop and commercialize 4D 150 in Asia Pacific markets and the Cystic Fibrosis Foundation which provides grant funding and strategic guidance for its pulmonology programs. These relationships help advance clinical development and prepare for eventual commercial launch. Payors including government health programs and private insurers will also become important customers once therapies receive approval as they determine coverage and reimbursement for the innovative gene therapy products. The company engages with patient advocacy groups to understand real world needs and to support education efforts that facilitate adoption by healthcare professionals.